Opus Genetics will launch a clinical trial of OPGx-MERTK, an adeno-associated virus gene therapy for MERTK-related retinitis pigmentosa, in Abu Dhabi with funding from the emirate’s Healthcare Research and Innovation Fund. Clinical development activities are slated to begin at Cleveland Clinic Abu Dhabi in 2026. There are no approved treatments for this rare form of RP, which Opus estimates affects about 60,000 patients worldwide.
The move centers the first-in-human program outside the traditional US/EU corridor and aligns Opus with Abu Dhabi’s Department of Health, Cleveland Clinic Abu Dhabi, M42’s Innovative Research Oversight and Support division, and the Authority of Social Contribution – Ma’an. The strategy marries local capital with a ready-made center of excellence for retinal surgery and imaging, allowing a single-site start that can compress site startup complexity for a subretinal, surgically delivered therapy. For a Nasdaq-listed developer navigating tight biotech capital markets, external funding and a partner-led infrastructure can extend runway while generating early human data in a region actively building rare disease capabilities.
Operationally, the choice of Cleveland Clinic Abu Dhabi concentrates the program in a facility with the technical depth to handle vector preparation, microinjection, perioperative immunomodulation, and high-resolution functional and structural assessments. That concentration raises execution stakes around vector manufacturing, release testing, and cross-border logistics for GMP material, along with long-term follow-up obligations typical of gene therapy. Patient identification will hinge on regional genetic testing pipelines and registries; Abu Dhabi’s emphasis on precision medicine and reported higher prevalence of inherited retinal diseases provides a recruitment rationale, but sponsors and partners will still need robust molecular confirmation workflows and data standards that map cleanly to ICH GCP expectations.
The decision has broader implications for sponsors and CROs evaluating the Middle East for advanced therapy trials. It signals a viable path for initiating gene therapy programs where funding, regulatory enablement, and site capability are bundled. For sites, it accelerates the build-out of surgical, imaging, and pharmacovigilance infrastructure tied to long-horizon gene therapy follow-up. For vendors, it opens demand for specialty logistics, local bioanalytical capacity, and real-world data systems designed for 5–15 years of surveillance. Regulators will be expected to demonstrate interoperability on data acceptability, electronic source standards, and safety reporting that can travel to FDA and EMA, as sponsors weigh whether a single-country dataset can bridge to US or EU programs or whether additional sites will be required.
What comes next will be defined by protocol design and regulatory choreography. Key signals to watch include dose-escalation schema, use of functional endpoints such as microperimetry alongside OCT-based structural measures, durability readouts beyond 6–12 months, and the immunogenicity profile in a subretinal AAV setting. Enrollment pace in 2026 will test the depth of the regional genetic referral network, and any plan to add ex-UAE sites will preview the global registration strategy. Manufacturing scale, vector release timelines, and the contours of long-term follow-up commitments will shape both cost and feasibility. The open question is whether early data generated in Abu Dhabi will be positioned as a cornerstone for global development or as a regional proof point requiring subsequent bridging studies in Western jurisdictions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
